Epidemiology of ovarian cancer in North Sardinia, Italy, during the period 1992-2010

Introduction: The aim of this study was to analyze and describe the incidence and mortality trends of ovarian cancer in North Sardinia, Italy, in the period 1992–2010. Materials and Methods: Data were obtained from the tumor registry of Sassari province which makes part of a wider registry web, coordinated today by the Italian Association for Tumor Registries. Results: The overall number of ovarian cancer cases registered in the period under investigation was 600. The mean age of the patients was 62 years. The standardized incidence and mortality rates were 11.2/100,000 and 5.1/100,000 respectively. A substantially stable trend in incidence and mortality of ovarian cancer was evidenced. Relative survival at five years from diagnosis was 44.2%. Conclusions: The incidence and mortality trends of ovarian cancer in North Sardinia remained relatively stable in the last decades, while prognosis remains relatively poor.

Ovarian cancer; Incidence; Mortality; Sardinia, Italy.

[1] World Health Organization: “Globocan 2012”. Available at: http://globocan.iarc.fr

[2] Pisani P., Bray F., Parkin D.M.: “Estimate of the worldwide prevalence of cancer for 25 sites in the adult population”. Int. J. Cancer, 2002, 97, 72.

[3] Miolo G., Bidoli E., Lombardi D., Santeufemia D.A., Capobianco G., Dessole F., et al.: “Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?” Arch. Gynecol. Obstet., 2012, 285, 499.

[4] Beard C.M., Hartmann L.C., Atkinson E.J., O’Brien P.C., Malkasian G.D., Keeney G.L., et al.: “The epidemiology of ovarian cancer: a population based study in Olmsted County, Minnesota. 1935-1991”. Ann. Epidemiol., 2000, 10, 14.

[5] Cossu A., Budroni M., Capobianco G., Pirino D., Palmieri G., Dessole S., et al.: “The incidence of female genital tumors in the Province of Sassari in the period 1992-2000”. Eur. J. Gynaecol. Oncol., 2004, 25, 96.

[6] Cossu A., Budroni M., Capobianco G., Pirino D., Palmieri G., Dessole S., et al.: “Epidemiological aspects of ovarian malignancies in North Sardinia in the period 1992-2001”. Eur. J. Gynaecol. Oncol., 2005, 26, 47.

[7] Budroni M., Cossu A., Paliogiannis P., Palmieri G., Attene F., Cesaraccio R., et al.: “Epidemiology of malignant pleural mesothelioma in the province of Sassari (Sardinia, Italy). A population-based report”. Ann. Ital. Chir., 2013, 28, 84.

[8] Paliogiannis P., Attene F., Cossu A., Budroni M., Cesaraccio R., Tanda F., et al.: “Lung cancer epidemiology in North Sardinia, Italy”. Multidiscip. Respir. Med., 2013, 12, 45.

[9] Cossu A., Budroni M., Paliogiannis P., Palmieri G., Scognamillo F., Cesaraccio R., et al.: “Epidemiology of thyroid cancer in an area of epidemic thyroid goiter”. J. Cancer Epidemiol., 2013, 2013, 584768. doi: 10.1155/2013/584768. Epub 2013 Mar 4.

[10] Palmieri G., Paliogiannis P., Scognamillo F., Budroni M., Cesaraccio R., Pulighe F., et al.: “Colorectal cancer epidemiology in an area with a spontaneous screening program”. Acta Medica Mediterr., 2013, 29, 231.

[11] Cossu A., Paliogiannis P., Attene F., Palmieri G., Budroni M., Sechi O., et al.: “Breast cancer incidence and mortality in North sardinia in the period 1992 – 2010”. Acta Medica Mediterr., 2013, 29, 235.

[12] Cherchi P.L., Marras V., Capobianco G., Ambrosini G., Piga M.D. Fadda G.M., et al.: “Immunohistochemical evaluation of a new epithelial antigen, Ber-Ep4 in ovarian cancer: preliminary results”. Eur. J. Gynaecol. Oncol., 2001, 22, 433.

[13] Cherchi P.L., Capobianco G., Ambrosini G., Fadda G.M., Piga M.D., Ruiu G., et al.: “Intracystic evaluation of tumor markers in benign and malignant ovarian pathology”. Eur. J. Gynaecol. Oncol., 2002, 23, 163.

[14] Capobianco G., Marras V., Meloni G.B., Dessole S., Ashqar N., Cherchi C., et al.: “Immunoishochemical evaluation of Ber-EP4 a new epithelial antigen in ovarian cancer: a propos of 62 cases”. Eur. J. Gynaecol. Oncol., 2012, 33, 90.

[15] Lorenzato A., Biolatti M., Delogu G., Capobianco G., Farace C., Dessole S., et al.: “AKT activation drives the nuclear localization of CSE1L and a pro-oncogenic transcriptional activation in ovarian cancer cells”. Exp. Cell. Res., 2013, 319, 2627.

[16] Hennessy B.T., Coleman R.L., Markman M.: “Ovarian cancer”. Lancet, 2009, 374, 1371.

[17] Riman T., Nilsson S., Persson I.R.: “Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies”. Acta Obstet. Gynecol. Scand., 2004, 83, 783.

[18] Bertone-Johnson ER.: “Epidemiology of ovarian cancer: a status report”. Lancet, 2005, 365, 101.

[19] Rota M., Pasquali E., Scotti L., Pelucchi C., Tramacere I., Islami F., et al.: “Alcohol drinking and epithelial ovarian cancer risk. A systematic review and meta-analysis”. Gynecol. Oncol., 2012, 125, 758.

[20] Jordan S.J., Whiteman D.C., Purdie D.M., Green A.C., Webb P.M.: “Does smoking increase risk of ovarian cancer? A systematic review. Gynecol. Oncol., 2006, 103, 1122.

[21] Italian Association for Tumor Registries (Associazione Italiana Registri Tumori, AIRTUM). Available at: http://www.registritumori.it/cms/

[22] Easton D.: “Breast cancer genes—what are the real risks?” Nat. Genet., 1997, 16, 210.

[23] Risch H.A., McLaughlin J.R., Cole D.E.C., Rosen B., Bradley L., Fan I., et al.: “Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer”. Am. J. Hum. Genet,, 2001, 68, 700.

[24] King M.C., Marks J.H., Mandell J.B.: “Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2”. Science, 2003, 302, 643.

[25] Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., HopperJ.L., et al.: “Average risks of breast and ovarian can cer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies”. Am. J. Hum. Genet., 2003, 72, 1117.

[26] Palomba G., Pisano M., Cossu A., Budroni M., Dedola M.F., Farris A., et al.: “Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian breast cancer patients through a hospital- based screening”. Cancer, 2005, 104, 1172.

[27] Palmieri G., Palomba G., Cossu A., Pisano M., Dedola M.F., Sarobba M.G., et al.: “BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling”. Ann. Oncol., 2002, 13, 1899.

[28] Palomba G., Loi A., Uras A., Fancello P., Piras G., Gabbas A., et al.: “A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population”. BMC Cancer, 2009, 9, 245.